SCHEMBL10272871

SCHEMBL10272871

CO/N=C(\C)c1cccc(CCCO/N=C(\C)c2cccc(-c3cccc(OC)c3)n2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
BACE1 P56817 1/20 0.39
CTSA P10619 2/20 0.38
LTB4R Q15722 1/20 0.38
ADORA1 P30542 3/20 0.36
ADORA3 P0DMS8 2/20 0.36
ADORA2B P29275 2/20 0.36
ADORA2A P29274 2/20 0.36
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SREBF2 Q12772 1/20 0.35
PTGDR Q13258 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10273816 0.88 PDE10A (0.36) CNR2IRAK4RAB9A
SCHEMBL10272878 0.81 KCNH2 (0.35) IRAK4NPC1RAB9ASMN1; SMN2
SCHEMBL882639 0.80 HSP90AA1 (0.33)
SCHEMBL882874 0.80 ALDH1A1 (0.43) CTSAADORA1ADORA3ADORA2AATP4A
SCHEMBL10273019 0.80 LIPG (0.33) CTSANPC1RAB9ASMN1; SMN2
SCHEMBL10272877 0.80 KCNH2 (0.36) IRAK4NPC1RAB9ASMN1; SMN2
SCHEMBL10272874 0.80 KCNH2 (0.34) NPC1RAB9ASMN1; SMN2
SCHEMBL16172520 0.80 KCNH2 (0.35) NPC1RAB9ASMN1; SMN2
SCHEMBL10272869 0.79 HSD17B14 (0.34) ALDH1A1HPGD
SCHEMBL882894 0.79 HSP90AA1 (0.38) NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
WO-2012038521-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309244-A1 NOVEL MICROBIOCIDES MSR1, C3AR1, CD209 CNR2 692/4885IRAK4 1726/4885BACE1 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.